Skip to main content
SpringerLink
Log in

Platelet Aggregation Studies and Coagulation Profile in Sickle Cell Disease in Symptomatic and Steady State Patients

  • ORIGINAL ARTICLE
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

To determine whether there is higher degree of platelet and/ or coagulation activation in sickle cell anaemia (SS) patients in complications and with clinical risk factors. A cross sectional study was conducted at a tertiary health care centre in central India with study groups: sickle cell disease (SCD): sickle cell anaemia (SS) and sickle cell trait (AS) consisting of 100 subjects each and controls (AA) with 40 subjects. Platelet aggregation (PA) with ADP, collagen and epinephrine, PT and aPTT were performed in all subjects and PA with ristocetin in ten candidates of each group. ANOVA and student’s unpaired t test were used to compare PA and coagulation profile of the three groups with respect to age groups, gender, present diagnosis, history of complications, frequency of hospital admissions (high ≥ 3/year) and frequency of blood transfusion (high > 2/year). The max PA% with ADP was significantly less in SS patients in steady state, which was even lesser in those having symptoms, complications in past/ present, high-frequency hospital admission and > 2 blood transfusions per year subgroups, as compared to all other groups and subgroups, but not consistently with collagen and epinephrine. The max PA % with ristocetin was least in SS with complications. No statistically significant difference in PT and aPTT values among the various clinical risk subgroups and groups was found. SCD patients can be monitored by using PA with ADP for their timely and better management. PA with ADP, PT and aPTT should be added to the workup of these patients for improved prognostication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ (2007) Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension and nitric oxide scavenging by cell-free hemoglobin. Blood 110:2166–2172. https://doi.org/10.1182/blood-2006-12-061697

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Alhawiti NM (2021) Hemostatic alteration in sickle cell disease: pathophysiology of the hypercoagulable state. King Khalid Univ J Health Sci 6:1–5

    Article  Google Scholar 

  3. Mehta P, Mehta J (1980) Abnormalities of platelet aggregation in sickle cell disease. J Pediatr 96(2):209–213. https://doi.org/10.1016/s0022-3476(80)80804

    Article  PubMed  CAS  Google Scholar 

  4. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E et al (1991) Pain in sickle cell disease. N Engl J Med 325:11–16. https://doi.org/10.1056/NEJM199107043250103

    Article  PubMed  CAS  Google Scholar 

  5. Wang WC, Lukens JN (1998) Sickle cell anemia and other sickling syndromes. In: Lee R, Lukens J, Greer JP, Rodgers GM, Paraskevas F, Foerster J (eds) Wintrobe’s clinical hematology. Williams & Wilkins, pp 1346–1397

    Google Scholar 

  6. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ et al (2000) Predicting adverse outcomes in children with sickle cell disease: a report from the cooperative study (CSSCD). N Engl J Med 342:83–89. https://doi.org/10.1056/NEJM200001133420203

    Article  PubMed  CAS  Google Scholar 

  7. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639–1644. https://doi.org/10.1056/NEJM199406093302303

    Article  PubMed  CAS  Google Scholar 

  8. Bashawri LA, Al-Mulhim AA, Ahmed MA, Bahnassi AA (2007) Platelet aggregation and physiological anticoagulants in sickle-cell disease. East Mediterr Health J 13(2):266–272 (PMID: 17684847)

    PubMed  CAS  Google Scholar 

  9. Gupta GK, Sarkar PD, Manyal R, Rajput MS (2022) Sickle cell disease: Assessment of hemostasis parameters in steady-state patients at tertiary care hospital, Indore. India Biomed Biotechnol Res J 6:81–85. https://doi.org/10.4103/bbrj.bbrj_162_21

    Article  Google Scholar 

  10. Chinawa JM, Emodi IJ, Ikefuna AN, Ocheni S (2013) Coagulation profile of children with sickle cell anemia in steady state and crisis attending the university of Nigeria teaching hospital, Ituku-Ozalla, Enugu. Niger J Clin Pract 16:159–163. https://doi.org/10.4103/1119-3077.110132

    Article  PubMed  CAS  Google Scholar 

  11. Dacie JV, Lewis SM (1994) Practical hematology, 8th edn. Churchill Livingstone, Edinburg, pp 320–325

    Google Scholar 

  12. Sarji KE, Eurenius K, Fullwood CO, Schraibman HB, Colwell JA (1979) Abnormalities of platelet aggregation in sickle cell anemia. Presence of a plasma factor inhibiting aggregation by ristocetin. Thromb Res 14(2–3):283–297. https://doi.org/10.1016/0049-3848(79)90238-x

    Article  PubMed  CAS  Google Scholar 

  13. Woulfe D, Yang J, Brass L (2001) ADP and platelets: the end of the beginning. J Clin Invest 107(12):1503–1505. https://doi.org/10.1172/JCI13361

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Sixma JJ, van Zanten GH, Huizinga EG, van der Plas RM, Verkley M, Wu YP et al (1997) Platelet adhesion to collagen: an update. Thromb Haemost 78:434–438 (PMID: 9198192)

    Article  PubMed  CAS  Google Scholar 

  15. Lanza F, Beretz A, Stierlé A, Hanau D, Kubina M, Cazenave JP (1988) Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol 255(6):H1276–H1288. https://doi.org/10.1152/ajpheart.1988.255.6.H1276

    Article  PubMed  CAS  Google Scholar 

  16. Leichtman DA, Brewer GJ (1977) A plasma inhibitor of ristocetin-induced platelet aggregation in patients with sickle hemoglobinopathies. Am J Hematol 2(3):251–258. https://doi.org/10.1002/ajh.2830020307

    Article  PubMed  CAS  Google Scholar 

  17. Buchanan GR, Holtkamp CA, Levy EN (1981) Racial differences in ristocetin-induced platelet aggregation. Br J Haematol 49(3):455–464. https://doi.org/10.1111/j.13652141.1981.tb07249.x

    Article  PubMed  CAS  Google Scholar 

  18. Raffini LJ, Niebanck AE, Hrusovsky J, Stevens A, Blackwood-Chirchir A, Ohene-Frempong K et al (2006) Prolongation of the prothrombin time and activated partial thromboplastin time in children with sickle cell disease. Pediatr Blood Cancer 47:589–593. https://doi.org/10.1002/pnc.20579

    Article  PubMed  Google Scholar 

  19. Kusfa IU, Aminu SM, Mamman AI, Hassan A, Babadoko AA, Mohammed MH et al (2018) Basic hemostatic parameters in adults with sickle cell anemia at Ahmadu Bello University Teaching Hospital. Zaria Nigeria Sahel Med J 21:157–161. https://doi.org/10.4103/smj.smj_2_17

    Article  Google Scholar 

  20. Kotila T, Adedapo K, Adedapo A, Oluwasola O, Fakunle E, Brown B (2005) Liver dysfunction in steady state sickle cell disease. Ann Hepatol 4:261–263 (PMID: 16432491)

    Article  PubMed  CAS  Google Scholar 

  21. Stathakis NE, Papayannis AG, Papayotas H, Scliros P, Gardakis C (1975) Hypercoagulability and hypofibrinolysis in sickle cell disease. Ann Hematol 31:355–364. https://doi.org/10.1007/BF01634001

    Article  CAS  Google Scholar 

  22. Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B et al (2016) A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med 374:625–635. https://doi.org/10.1056/NEJMoa1512021

    Article  PubMed  CAS  Google Scholar 

  23. Wun T, Soulieres D, Frelinger AL, Krishnamurti L, Novelli EM, Kutlar A et al (2013) A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol 6:17. https://doi.org/10.1186/1756-8722-6-17

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Desai PC, Brittain JE, Jones SK, McDonald A, Wilson DR, Dominik R et al (2013) A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thromb Res 132:341–345. https://doi.org/10.1016/jthromres.2013.08.002

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Semple MJ, Al-Hasani SF, Kioy P, Savidge GF (1984) A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost 51:303–306 (PMID: 6388012)

    Article  PubMed  CAS  Google Scholar 

  26. Zago MA, Costa FF, Ismael SJ, Tone LG, Bottura C (1984) Treatment of sickle cell diseases with aspirin. Acta Haematol 72:61–64. https://doi.org/10.1159/000206360

    Article  PubMed  CAS  Google Scholar 

  27. Noubouossie D, Key NS, Ataga KI (2016) Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev 30(4):245–256. https://doi.org/10.1016/j.blre.2015.12.003

    Article  PubMed  CAS  Google Scholar 

  28. Sparkenbaugh EM, Chantrathammachart P, Mickelson J, van Ryn J, Hebbel RP, Monroe DM et al (2014) Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 123:1747–1756. https://doi.org/10.1182/blood-2013-08-523936

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Sparkenbaugh E, Pawlinski R (2013) Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol 162:3–14. https://doi.org/10.1111/bjh.12336

    Article  PubMed  CAS  Google Scholar 

  30. Arumugam PI, Mullins ES, Shanmukhappa SK, Monia BP, Loberg A, Shaw MA et al (2015) Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice. Blood 126:1844–1855. https://doi.org/10.1182/blood-2015-01-625707

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

We are greatful to Dr W. K. Raut, ex Professor and Head of Department of Pathology, GMCH, Nagpur for his unrelenting support and guidance for this work.

Funding

The authors did not receive support from any organization for the submitted work.

Author information

Authors and Affiliations

  1. Department of Pathology, Government Medical College and Hospital, Nagpur, India

    Vaishali B. Nagose, Purnima M. Kodate, Dinkar T. Kumbhalkar & Suprita P. Nayak

  2. Department of Pathology, Government Medical College, Sindhudurg, India

    Vaishali B. Nagose

  3. Department of Physiology, Dr Ulhas Patil Medical College and Hospital, Nagpur, India

    Shivanand S. Rathod

Authors
  1. Vaishali B. Nagose
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Purnima M. Kodate
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dinkar T. Kumbhalkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shivanand S. Rathod
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Suprita P. Nayak
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by VBN, PMK and SSR. The first draft of the manuscript was written by VBN and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Vaishali B. Nagose.

Ethics declarations

Conflict of interest

The authors have no competing interests to declare that are relevant to the content of this article.

Ethical Approval

The study was approved by the institutional ethics committee (Government medical college, Nagpur). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments comparable ethical standards.

Informed Consent

A written informed consent to participate in the study was obtained from all the participants or their parent or legal guardian in the case of children under 16 years of age.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nagose, V.B., Kodate, P.M., Kumbhalkar, D.T. et al. Platelet Aggregation Studies and Coagulation Profile in Sickle Cell Disease in Symptomatic and Steady State Patients. Indian J Hematol Blood Transfus (2023). https://doi.org/10.1007/s12288-023-01703-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12288-023-01703-9

Keywords

Search

Navigation